Posted by Michael Wonder on 29 Nov 2021
FDA approves new imaging drug to help identify ovarian cancer lesions
29 November 2021 - The U.S. Food and Drug Administration today approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions.
The drug is designed to improve the ability to locate additional ovarian cancerous tissue that is normally difficult to detect during surgery.
